Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Indenebart by AstraZeneca for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration): Likelihood of Approval
Indenebart is under clinical development by AstraZeneca and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome...